Generic Name and Formulations:
Alglucosidase alfa 5mg/mL; pwd for IV infusion after reconstitution and dilution; preservative-free.
Sanofi Genzyme Company
Indications for LUMIZYME:
Pompe disease (GAA deficiency).
Adults and Children:
Give by IV infusion over 4 hours. 20mg/kg every 2 weeks. Initial infusion rate: 1mg/kg/hr; may increase by 2mg/kg/hr every 30 minutes, if tolerated, to max 7mg/kg/hr.
Discontinue immediately if severe anaphylactic or allergic reactions develop; have appropriate medical support measures available and during rechallenge. Increased risk of acute cardiorespiratory failure with acute underlying respiratory illness or compromised cardiac function. Cardiac hypertrophy (increased risk of cardiac arrhythmia when given general anesthesia for central venous catheter placement). Infants with cardiac dysfunction may require prolonged observation times. Monitor for development of systemic immune complex-mediated reactions; consider discontinuing if occurs. Monitor for IgG antibody formation every 3 months for 2 years, then annually. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Hydrolytic lysosomal glycogen-specific enzyme.
Hypersensitivity reactions, anaphylaxis, rash, purexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension, pallor, rigors, tremor, vomiting, fatigue, myalgia.
Only available through Lumizyme ACE Program. To enroll call (800) 745-4447.
Single-use vial (50mg)—1, 10
Clinical Pain Advisor Articles
- Manual Therapy vs Opioids for Management of Shoulder, Spine Pain
- Kinesiophobia May Be Associated With Greater Cutaneous Allodynia in Migraine
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain
- Topical Migraine Trigger Point Treatment as Effective as Injection
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Prescription Digital Therapeutic Approved for Opioid Use Disorder
- Persistence of Post-Traumatic CRPS Associated With Initial Pain Sensitization
- Blunted Cardiovascular Stress Reactivity in Fibromyalgia With Comorbid PTSD
- Name-Brand Medications Driving Spike in U.S. Drug Spending
- Physician Responsibility to Combat "Fake News" in Medicine
- The Future Of Robot Physicians: Is Artificial Intelligence Poised to Take Over Medicine?
- Chronic Spinal Pain and Depression: Does One Represent a Risk Factor for the Other?